Abatacept to induce remission of peanut allergy during oral immunotherapy (ATARI): protocol for a phase 2a randomized controlled trial

Abatacept to induce remission of peanut allergy during oral immunotherapy (ATARI): protocol for a phase 2a randomized controlled trial

ContextWhile oral immunotherapy (OIT) has been shown to promote the remission of mild peanut allergy in young children, there is still an unmet need for a disease-modifying intervention for older patients and those with severe diseases. In mice models, abatacept, a cytotoxic T lymphocyte-associated...

Full description

Bibliographic Details
Main Authors: Camille Braun, Pauline Azzano, Florence Gingras-Lessard, Émilie Roy, Kathryn Samaan, François Graham, Louis Paradis, Anne Des Roches, Philippe Bégin
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Medicine
Subjects:
food allergy
oral immunotherapy (OIT)
sustained unresponsiveness
abatacept
CTLA-4
peanut allergy
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1198173/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1198173/full

Similar Items